<DOC>
	<DOCNO>NCT02823808</DOCNO>
	<brief_summary>All subject randomize Alo/Pio combo group ( intervention ) Glim/Met combo group ( control ) intensive COAD treatment base identical protocol . - All subject manage daily , fix dose , single tablet treatment base study protocol , followed-up 104 week . - Any group subject fail reach glycemic target single tablet treatment , subject treat rescue medication stop regular observation .</brief_summary>
	<brief_title>Effect Alogliptin/Pioglitazone Preservation Long-term Beta-cell Function</brief_title>
	<detailed_description />
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 Diabetes Mellitus patient Patient diagnose within previous 12 month HbA1c level 8.012.0 % , medical history relate diabetes , display proliferative retinopathy The use weightlowering drug , investigational bloodglucose lipidlowering agent ( statins ezetimibe ) within past 3 month Previous treatment systemic corticosteroid change dosage thyroid hormones previous 6 week The use insulin within 3 month prior screen Others</criteria>
	<gender>All</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>